Skip to main content

Table 6 Univariate and multivariate analyses for early recurrence in those receiving endocrine therapy alone (early vs no recurrence)

From: Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence

  Early vs no recurrence in endocrine therapy group
  Univariate analysis p Value Multivariate analysis p Value
ALDH1, ≤1 %/>1 % 1.804 (0.651–4.609) 0.244 Not selected  
Age, ≤50/>50 years 0.996 (0.526–1.932) 0.992 Not selected  
Tumor size, ≤20/>20 mm 6.182 (3.208–12.383) <0.001 4.910 (2.469–10.076) <0.001
Nodal metastasis negative/positive 3.344 (1.543–7.181) 0.002 2.894 (1.229–6.777) 0.002
Progesterone receptor staining, <20 %/≥20 % 0.708 (0.382–1.313) 0.272 Not selected  
Ki-67 staining, <20 %/≥20 % 1.441 (0.619–3.159) 0.383 Not selected  
Tumor grade 1 or 2/3 2.615 (1.666–4.128) <0.001 2.820 (1.296–6.111) <0.001
  1. ALDH1 aldehyde dehydrogenase 1